News

GLP-1 receptor agonists work by enhancing insulin section, reducing glucagon release and improving glucose control and satiety. They include Liraglutide (Saxenda, Victoza), Dulaglutide (Trulicity) and Semaglutide (Wegovy, Ozempic, Rybelsus). Tirzapatide (Mounjaro) is both a GLP-1 receptor agonist and GIP analog.  The GLP-1 receptor agonists currently licensed for weight management in the UK are Saxenda, Wegovy and Mounjaro, while Victoza, Trulicity, Ozempic and Rybelsus are licensed for use in the management of type 2 diabetes.

Category

• News

We are seeking an experienced and respected leader with a strong background in obesity care or a related healthcare or academic field. You will bring:

Category

• News

This joint position statement was produced in June 2025 by the Society for Endocrinology and Obesity Management Collaborative UK in collaboration with The Association for the Study of Obesity, Royal College of Physicians, NHS England, British Obesity & Metabolic Surgery Society, and All About Obesity. 

Download Position Statement

Category

• News

Tirzepatide (Mounjaro®) is accepted for restricted use within NHS Scotland by the SMC.

Full details

Category

• News

As of June 2024, the National Institute for Health and Care Excellence (NICE) has issued draft recommendations the use of Mounjaro as a treatment for overweight or obesity. 

Category

• News

A joint position statement by the Society for Endocrinology and Obesity Management Collaborative UK

This position statement is aimed at healthcare professionals working within weight management services, organisations delivering medical therapies for patients living with obesity, and commissioners of such services. Its objectives are to: 

Category

• News

Published in The Lancet, in June 2023, read this publication on the future of obesity care in the UK.

DOI :https://doi.org/10.1016/S0140-6736(23)01083-8

Full publication

Category

• News